Juvabis designs next-generation antibacterial therapeutics that withstand mechanisms of bacterial drug-resistance and at the same time display superior tolerability due to increased target selectivity by rational design. Juvabis has been founded around a proprietary technology developed by researchers at the University of Zurich, and a pipeline of early drug candidates discovered in collaboration with researchers at the ETH Zurich and Wayne State University in Detroit.
| Website | http://www.juvabis.com |
| Revenue | $4 million |
| Employees | 3 (0 on RocketReach) |
| Technologies |
JavaScript
,
HTML
,
G Suite
+5 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Business Services General, Business Services |
| Keywords | Antibacterial Therapeutics, New Antibiotics, Drug Resistance, Rational Drug Design, Antibacterial Agents, Antimicrobial Resistance, Pharmaceutical Research, Bacterial Infections, Antimicrobial Peptides, Drug Development, Pharmaceutical Development, Drug Discovery, Biotechnology, Therapeutics |
| Competitors | Trulieve, Cresco Labs, Curaleaf, Tilray Brands, Inc., Canopy Growth Corporation, Organigram Inc, MedMen, OGEN, Hexo, Aphria +31 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies |
Looking for a particular Juvabis AG employee's phone or email?
Juvabis AG Questions
The Juvabis AG annual revenue was $4 million in 2026.
The NAICS codes for Juvabis AG are [3254, 32, 325, 32541].
The SIC codes for Juvabis AG are [283, 28].
Related Companies
